- For Patients
- Introduction to the Marshall Protocol
- Length of the MP
- Immunopathology
- Managing immunopathology
- Food and drink
- Light restriction
- Vitamin D metabolite calculator - get feedback on vitamin D results
- Therapeutic probe - best method for determining MP suitability
- Starting the Marshall Protocol
- Resources for patients
- Marshall Protocol summary
- Palliative vs. curative treatments
- Patient interviews on Bacteriality
- Non-MP treatments
- Glossary
- The Protocol
- Marshall Protocol summary
- Publications and presentations
- Science behind immunopathology
- Science behind olmesartan (Benicar)
- Safety of olmesartan
- Resources for physicians
- Vitamin D metabolite calculator - get feedback on vitamin D results
- Therapeutic probe - best method for determining MP suitability
- Physicians' concerns about the MP
- Notice for emergency medical personnel
- The Pathogenesis
- Publications and presentations
- Science behind Marshall Pathogenesis
- Microbes in the human body
- Successive infection and variability in disease
- Autoimmune theory of disease
- Science behind vitamin D
- Metabolism of vitamin D and the VDR
- Th1 Spectrum Disorder - how chronic inflammatory diseases are related
- Transmission of bacteria and onset of chronic disease
- Evolutionary perspective on disease
- Incidence and prevalence of disease
- Evidence that chronic disease is caused by pathogens
- Diseases
- Foundation
- Related Sites
Differences
This shows you the differences between two versions of the page.
| Both sides previous revisionPrevious revisionNext revision | Previous revisionNext revisionBoth sides next revision | ||
| home:othertreatments:anticonvulsants [09.10.2010] – external 127.0.0.1 | home:othertreatments:anticonvulsants [10.25.2018] – [Types of anticonvulsant and anti-seizure agents] sallieq | ||
|---|---|---|---|
| Line 9: | Line 9: | ||
| Patients should work with their physician to wean from these drugs when their symptoms become tolerable. | Patients should work with their physician to wean from these drugs when their symptoms become tolerable. | ||
| - | |||
| - | |||
| =====Types of anticonvulsant and anti-seizure agents ===== | =====Types of anticonvulsant and anti-seizure agents ===== | ||
| - | * baclofen (Lioresal) | ||
| * carbamazepine (Carbatrol, Equetro, Novo-Carbamazepine, | * carbamazepine (Carbatrol, Equetro, Novo-Carbamazepine, | ||
| * carisoprodol (Soma) | * carisoprodol (Soma) | ||
| + | * chininsulfat (Chinin) | ||
| * clonazepam (Klonopin) | * clonazepam (Klonopin) | ||
| * divalproex sodium (Depakote) | * divalproex sodium (Depakote) | ||
| Line 28: | Line 26: | ||
| + | {{tag> | ||
| + | ===== Notes and comments ===== | ||
| - | |||
| - | {{tag> | ||
| - | |||
| - | ===== Notes and comments ===== | ||
| - | EDIT | ||
| * Legacy content | * Legacy content | ||
| * | * | ||
| ===== References ===== | ===== References ===== | ||
home/othertreatments/anticonvulsants.txt · Last modified: 09.14.2022 by 127.0.0.1
© 2015, Autoimmunity Research Foundation. All Rights Reserved.